NASDAQ:ADPT - Adaptive Biotechnologies Stock Price, News & Analysis

-1.71 (-3.58 %)
(As of 08/18/2019 03:52 PM ET)
Today's Range
Now: $46.10
50-Day Range N/A
52-Week Range
Now: $46.10
Volume607,800 shs
Average Volume417,392 shs
Market Capitalization$5.73 billion
P/E RatioN/A
Dividend YieldN/A
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:ADPT



Sales & Book Value

Annual SalesN/A
Book Value($2.29) per share



Market Cap$5.73 billion
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ADPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.

Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $1.08. The business had revenue of $22.10 million for the quarter, compared to the consensus estimate of $19.39 million. The firm's revenue for the quarter was up 90.5% compared to the same quarter last year. View Adaptive Biotechnologies' Earnings History.

When is Adaptive Biotechnologies' next earnings date?

Adaptive Biotechnologies is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Adaptive Biotechnologies.

What price target have analysts set for ADPT?

7 brokers have issued twelve-month target prices for Adaptive Biotechnologies' stock. Their predictions range from $32.00 to $47.00. On average, they expect Adaptive Biotechnologies' stock price to reach $43.00 in the next year. This suggests that the stock has a possible downside of 6.7%. View Analyst Price Targets for Adaptive Biotechnologies.

What is the consensus analysts' recommendation for Adaptive Biotechnologies?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptive Biotechnologies.

Has Adaptive Biotechnologies been receiving favorable news coverage?

Media stories about ADPT stock have trended negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adaptive Biotechnologies earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Adaptive Biotechnologies.

Who are some of Adaptive Biotechnologies' key competitors?

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Home Depot (HD), Honeywell International (HON), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), Mcdonald's (MCD), Raytheon (RTN) and Amgen (AMGN).

Who are Adaptive Biotechnologies' key executives?

Adaptive Biotechnologies' management team includes the folowing people:
  • Mr. Chad M. Robins M.B.A, Co-Founder, CEO & Chairman (Age 44)
  • Ms. Julie Rubinstein, Pres (Age 47)
  • Dr. Harlan S. Robins Ph.D., Co-Founder & Chief Scientific Officer (Age 45)
  • Mr. Christopher Carlson Ph.D., Founder
  • Mr. Chad M. Cohen, Chief Financial Officer (Age 44)

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

When did the company's quiet period expire?

Adaptive Biotechnologies' quiet period expired on Tuesday, August 6th. Adaptive Biotechnologies had issued 15,000,000 shares in its IPO on June 27th. The total size of the offering was $300,000,000 based on an initial share price of $20.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (32.42%), Senator Investment Group LP (4.32%), Price T Rowe Associates Inc. MD (0.76%), BlackRock Inc. (0.56%), Bamco Inc. NY (0.55%) and Rock Springs Capital Management LP (0.51%). Company insiders that own Adaptive Biotechnologies stock include Chad M Cohen, Nancy Louise Hill and Viking Global Performance Llc. View Institutional Ownership Trends for Adaptive Biotechnologies.

Which major investors are buying Adaptive Biotechnologies stock?

ADPT stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Senator Investment Group LP, Price T Rowe Associates Inc. MD, BlackRock Inc., Bamco Inc. NY, Rock Springs Capital Management LP, TimesSquare Capital Management LLC and JPMorgan Chase & Co.. Company insiders that have bought Adaptive Biotechnologies stock in the last two years include Chad M Cohen, Nancy Louise Hill and Viking Global Performance Llc. View Insider Buying and Selling for Adaptive Biotechnologies.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $46.10.

How big of a company is Adaptive Biotechnologies?

Adaptive Biotechnologies has a market capitalization of $5.73 billion. Adaptive Biotechnologies employs 346 workers across the globe.View Additional Information About Adaptive Biotechnologies.

What is Adaptive Biotechnologies' official website?

The official website for Adaptive Biotechnologies is

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company can be reached via phone at 206-659-0067 or via email at [email protected]

MarketBeat Community Rating for Adaptive Biotechnologies (NASDAQ ADPT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  46
MarketBeat's community ratings are surveys of what our community members think about Adaptive Biotechnologies and other stocks. Vote "Outperform" if you believe ADPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by Staff

Featured Article: Return on Equity (ROE)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel